
At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier
At first, the SERENA-6 trial (NCT04964934) seemed a typical choice for the plenary session of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. It involved a new therapy, camizestrant (AstraZeneca), the first next- …